## Q3 Investor/Earnings Call

#### Immune Responses, On Cue™

Harnessing the Potential of the Human Immune System to Treat Cancer

#### Nasdaq: CUE

November 14, 2022



#### **Disclaimers**

This presentation has been prepared by Cue Biopharma, Inc. ("we," "us," "our," "Cue" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forwardlooking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future, "vision", "likely" or other comparable terms. All statements other than statements of historical facts included in this presentation regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding our development plans for CUE-101, CUE-102 and the continued buildout of our pipeline, the sufficiency of our cash, cash equivalents and marketable securities to support the clinical development of CUE-101 and CUE-102, anticipated results of our drug development efforts, including study results, our expectations regarding the timing of milestone events, regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies, our ability to secure required U.S. Food and Drug Administration ("FDA") or other governmental approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on our operations and clinical trials; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; our reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; our ability to obtain adequate financing to fund our business operations in the future; our ability to maintain and enforce necessary patent and other intellectual property protection, competitive factors, general economic and market conditions; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this presentation is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.



#### Agenda

- Introduction
- Immuno-STATS: TCR-selective Engagers
- Clinical Update
  - CUE-101: Representative of IL-2 based CUE-100 series
  - CUE-102: Targeting WT1+ cancers
- 3Q-FY22 Financial Results
- Concluding Remarks
- Q&A

Dan Passeri, CEO Anish Suri, President and CSO Dr. Ken Pienta, Acting CMO Dr. Matteo Levisetti, SVP, Clin. Development

Kerri-Ann Millar, CFO Dan Passeri, CEO All



## **Immuno-STAT™ (IST) Platform:** TCR-selective Engagers of Tumor-specific T cells


- CUE-100 Series: TCR engagers that selectively target IL-2 to tumor-specific T cells
  - Creates a therapeutic index for harnessing the potential of IL-2 in immuno-oncology
- Clinical Validation via CUE-101 (HPV+ R/M HNSCC)
  - Monotherapy efficacy in late-stage 3L+ patients (RECIST-based OR and SDs; significant increase in mOS)
  - Combination Tx with CPI in 1L patients (current RECIST-based 40% ORR at RP2D, and SDs; survival data maturing)
  - Favorable tolerability profile observed to date (>65 patients dosed across mono-tx and combo-tx trials)
- Platform modularity enables efficient pipeline expansion into multiple cancers
  - CUE-102 (WT-1: CRC, Gastric, Pancreatic, Ovarian) de-risked by CUE-101 clinical data: Ph 1 ongoing
  - Phase 1 dose escalation shortened due in part to favorable tolerability profile demonstrated to date by CUE-101
  - Neo-STAT<sup>TM</sup> enables targeting multiple tumor Ags to maximize time and cost efficiencies to expand pipeline

#### Milestones and potential value drivers

- CUE-101 Monotherapy mOS potential registration path
- CUE-101 Combination with Pembrolizumab to date  $ORR \ge 40\% / mOS$  supports potential registration path




#### Tumor-specific T cells are <u>Key</u> for Successful Immunotherapy of Cancers





### **CUE-100 Series ISTs:** TCR-selective targeting of IL-2 to Tumor-specific T cells



#### **CUE-100 Series Design**


- Single biologic molecule
- Ab-like manufacturability and CMC
- Stable, off-the-shelf
- IV (or SC) administration



- Engagement of the "right T cell" results in co-stimulation of TCR and IL-2 receptor (IL-2R)
- ✓ Limits systemic activation of irrelevant T cells
- ✓ *Designed to create a therapeutic index for IL-2*
- Provides PoC and mechanistic basis for targeting numerous other cytokines and activation signals




#### **CUE-100 Series:** Potential for Best-in-Class IL-2






### **CUE-100 Series ISTs:** Selectivity and Activity





### **CUE-101 Provides Clinical PoC and Platform De-risking**



Head & Neck*						
Anal						
Cervical						
Penile						
Vulvar						

\* Ongoing clinical trial

- CUE-101 Monotherapy in 3L+ R/M HNSCC
- CUE-101 + Pembrolizumab Combination in 1L R/M HNSCC
- CUE-101 Neo-adjuvant trial in locally/advanced HNSCC
  - Trial ongoing at Washington University in St. Louis




### **CUE-101:** Monotherapy Efficacy in 3L+ R/M HNSCC Patients


✓ Demonstration of single-agent anti-tumor efficacy

- *RECIST-based PR and Durable Stable Disease in 3L+ R/M HNSCC patients*
- mOS benefit emerging from survival follow-up
- ✓ Selective expansion of tumor-specific T cells and NK cells
- ✓ T cell infiltration into tumor and increased tumor necrosis
- ✓ Tolerability at clinically active doses
- Sustained drug exposure upon repeated dosing with no clinical evidence of immunogenicity to date
- ✓ Fast Track Designation granted




### CUE-101 Monotherapy Patient Data: PK, PD and Tumor Infiltration







#### T cell infiltration into tumors post-CUE-101 Tx



#### Tumor necrosis post-CUE-101 Tx



### Patterns of Clinical Efficacy in Patients with CUE-101 Monotherapy




- Rapid tumor reduction and durable PR
- On treatment ~ 1 year

- Durable SD which may be pathologic CR
- Remains on treatment > 1 year with no evidence of HPV cfDNA
- Durable SD
- Remains on treatment > 1 year




#### Increased Overall Survival in 3L+ Patients Treated with CUE-101 Monotherapy (n=20)



Overall survival in months for all monotherapy patients treated in CUE-101-01, at 4 mg/kg, from time of 1st dose of drug (Cycle 1 Day 1). PR (partial response) is indicated by a green circle; Durable SD (stable disease) is indicated by a hatched orange circle (requires SD at ≥ 2 consecutive scans at 6-week and 12-week visits). \*\* Onset and duration of the response is not indicated on the plot. Kaplan-Meier Analysis CUE-101 mOS 13.3 month; [95% Confidence Interval (9.1, NA)].




# CUE-101 in Combination with Pembrolizumab in 1L R/M HNSCC: 40% ORR at 4 mg/kg RP2D




14

## **CUE-101:** Case Study – Confirmed PR in Combo Patient (2 mg/kg + pembrolizumab)






#### **CUE-101:** Case Study – Confirmed PR in Combo Patient (4 mg/kg + pembrolizumab)



#### **Overall Survival by Dose in CUE-101 Combination Therapy Patients**





17

#### **Registrational Path Options**

- CUE-101 Monotherapy
  - Fast Track Designation granted for the treatment of R/M HPV+ HNSCC
  - Potential Phase 3 registrational trial option: CUE-101 vs. Investigator's Choice of chemotherapy in patients that have failed prior chemo and CPI, Primary Endpoint: Overall Survival

#### • CUE-101 Combination therapy with pembrolizumab


- Fast Track Designation granted for the treatment of R/M HPV+ HNSCC
- On track for completion of enrollment of expansion cohort (n=20)
- Potential Phase 3 registrational trial option: CUE-101 + pembrolizumab vs pembrolizumab in 1L R/M HNSCC patients, Primary Endpoints: ORR, PFS; Secondary Endpoints: OS, PROs

**FDA Fast Track Designation** (granted 10/03/2022) facilitates the development and expedited review of new drugs that treat a serious medical condition and fill an unmet medical need by providing:

- More frequent meetings and written communication with the FDA
- Eligibility for Accelerated Approval and Priority Review if criteria are met
- Rolling review



# **CUE-102 Wilms Tumor 1 (WT1):** Broad Potential Opportunity in Multiple Solid and Heme Cancers




- IND approval for CUE-102 harnessed the clinical de-risking observed with CUE-101, leading to potential advantages:
  - Clinical development efficiencies (approval to start at a higher dose and minimize cohorts for dose escalation)
  - Regulatory advantages (FDA did not require additional IND tox)
- CUE-102 targets a dominant T cell epitope from WT1
- WT1 is an attractive onco-fetal tumor antigen with significant expression in numerous solid and heme cancers
  - Solid: CRC, Ovarian, Lung, Gastric, Pancreatic, Breast, GBM
  - Heme: AML/MDS, ALL, MM

#### Phase 1 Monotherapy Trial Currently Enrolling (NCT05360680)



## CUE-101 Accelerates CUE-102 Clinical Development by Enabling Dose Escalation to Start at 1 mg/ kg




Abbreviations: Q3W, once every 3 weeks; rhIL-2, recombinant human interleukin-2; RP2D, Recommended Phase 2 Dose



# **CUE-100 Series:** Broad Potential Opportunities in Cancer Immunotherapy

We believe clinical PoC with CUE-101 de-risks and validates CUE-100 series

Structural similarity creates potential regulatory and development efficiencies





### Cue Biopharma, Inc: Q3 2022 Financial Highlights

Cue Biopharma, Inc. Selected Consolidated Statement of Operations Data ( <u>in</u> thousands, except share data)					
		Three Months Ended September 30,			
		2022		2021	
Collaboration revenue	\$	68	\$	2,395	
Operating expenses:					
General and administrative		3,528		4,125	
Research and development		7,571		11,288	
Total operating expenses		11,099		15,413	
Loss from operations		(11,031)		(13,018)	
Other income:					
Total other income, net		76		25	
Net Loss	\$	(10,955)	\$	(12,993)	
Net loss per common share – basic and					
diluted	\$	(0.31)	\$	(0.41)	
Weighted average common shares outstanding – basic and diluted		35,383,430		31,315,178	

Cue Biopharma, Inc. **Selected Consolidated Balance Sheet Data** (in thousands) September 30, December 31, 2022 2021 Cash and cash equivalents 29,726 64,371 Marketable securities 29,457 -Total current assets 61,700 68,469 Working Capital 51,478 55,681 Total assets 76,300 83,401 Total Stockholders' equity 50,764 65,492



#### **Upcoming Anticipated Key Milestones**

- CUE-101 Monotherapy (mature mOS data EOY 2022 define potential registrational trial mid 2023)
- CUE-101 + pembrolizumab Combination Therapy (preliminary ORR 2Q 2023 on 20 patients with potential registrational trial being defined by EOY 2023)
- CUE-102 Monotherapy (data from dose escalation by mid 2023-significant potential market opportunities for WT1 positive cancer indications)
- We believe maturing clinical datasets may catalyze significant BD/Corp Dev opportunities for pipeline expansion



## **Thank You**

#### Immune Responses, On Cue™

Harnessing the Potential of the Human Immune System to Treat Cancer

